Are GI cancers still marooned on an island or are they catching up with other solid tumours in terms of progress?
San Francisco – In the past, whenever I posted updates on any of the GI cancers they attracted noticeably less attention than other solid tumours and rightly so, especially given the lack of new agents and compelling data. If the highlight of a meeting is debating the merits of left versus right side tumour responses or bolus versus infusional administration then the plot has kind of been lost in the morass of abstracts available.
This year, however, things are looking up with a tidy group of studies that have what I call ‘interestingness’ – in other words, results that will tempt us to look deeper rather than merely skim in the hope of something new and shiny.
This weekend in San Francisco saw some highlights (and also lowlights) in the form of new clinical data emerging from the 2020 ASCO GI conference. That means we’re due a review so let’s rock ’n roll though the important studies to see what stands out from the crowd…
To learn more from our oncology coverage and get a heads up on our latest conference analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
For what seems the longest time, we have seen the battle in metastatic clear cell renal cell carcinoma (ccRCC) being focused on various anti-VEGF TKIs, whether against interferon, mTOR inhibitors, and even each other.
Lately, anti-PD(L)1 antibodies have also come on the scene – both as monotherapy and in different combinations – so are things set to change?
Will it be plaining sailing or are there hidden dangers ahead for the unwary?
Here, we take a look at the ever evolving landscape in RCC and explore the issues and challenges surrounding some of the novel combination readouts, including a look at the role immuno-oncology might play going forward.
Not surprisingly, there’s a lot to consider, discuss and think about…
To learn more and get a heads up on our latest conference and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
It’s that time of the year again already… the ASCO GU Preview series! The good news is that there is a bumper crop of intriguing data to discuss this year.
Golden Gate Bridge, San Francisco
With the ASCO embargo on the GU Symposium in San Francisco lifting at 5pm, there’s a lot to consider not merely in terms of the data itself, but more importantly, in terms of a broader context and the landscapes involved in prostate, renal and urothelial cancers.
Here we take a look at some of the key highlights to watch out for and what they mean in context.
A separate post on the phase 3 PROSPER data for enzalutamide in prostate cancer with a discussion on the ongoing enzalutamide/abiraterone/ADT/chemotherapy debate as part of the GU18 coverage is also available.
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
I was recently in San Francisco so thought I would continue my theme of writing about biotechnology regions that I visit around the United States.
Growing up in England, I remember listening to the radio broadcasts of the late Alistair Cooke, who from 1946 to 2004 shared his “Letter from America“; the longest running radio programme ever produced. In the pre-internet era his mixture of anecdotes, insights and reflections reminds me of modern day blogs.
San Francisco remains a favorite city of mine. Fueled by access to venture capital and proximity to major research universities such as Stanford, University of California at Davis, Berkelely & San Francisco, start-up companies continue to thrive in the Bay area. BayBio, Northern California’s Life Science Association runs many excellent events. Their annual conference in April is focused on “Powering Global Innovation.”
The anchor tenant in the San Francisco biotech mall remains Genentech, and no other company in the area has had the same growth trajectory. What catapults a company forward is a combination of a breakthrough product and ability to capture its value. The licensing deals and acquisitions we see today in the biotechnology industry, to some degree limit the ability of emerging biotech companies to repeat Genentech’s model. Risk sharing, partnering and the desire of venture capitalists for an early return on investment, all limit the ability of a biotech company to make it to the major leagues. In the end, even Genentech ended up being acquired by Roche.
What’s the future in San Francisco? It remains a high cost place to live but with a pool of talent in the entrepreneurial culture of the West Coast. There is also the uncertainty about the California economy and the cost of doing business, which is most likely set to increase. In some way, my impression is that San Francisco has not quite taken off as a biotechnology city in the same way that Boston and Cambridge has. Feel free to comment if you disagree or have an opinion otherwise.